We fine mapped two primary biliary cirrhosis (PBC) risk loci, CLEC16A (C-type lectin domain family 16 member A) --suppressor of cytokine signaling 1 (SOCS1) and Spi-B protein (SPIB) and sequenced a locus, sialic acid acetylesterase (SIAE), proposed to harbor autoimmunity-associated mutations. In all, 1450 PBC cases and 2957 healthy controls were genotyped for 84 single-nucleotide polymorphisms (SNPs) across the CLEC16A-SOCS1 and SPIB loci. All 10 exons of the SIAE gene were resequenced in 381 cases and point substitutions of unknown significance assayed for activity and secretion. Fine mapping identified 26 SNPs across the CLEC16A-SOCS1 and 11 SNPs across the SPIB locus with significant association to PBC, the strongest signals at the CLEC16A-SOCS1 locus emanating from a SOCS1 intergenic SNP (rs243325; P ¼ 9.91 Â 10 À9 ) and at the SPIB locus from a SPIB intronic SNP (rs34944112; P ¼ 3.65 Â 10 À9 ). Among the associated SNPs at the CLEC16A-SOCS1 locus, two within the CLEC16A gene as well as one SOCS1 SNP (rs243325) remained significant after conditional logistic regression and contributed independently to risk. Sequencing of the SIAE gene and functional assays of newly identified variants revealed six patients with functional non-synonymous SIAE mutations (Fisher's P ¼ 9 Â 10 À4 vs controls) We demonstrate independent effects on risk of PBC for CLEC16A, SOCS1 and SPIB variants, while identifying functionally defective SIAE variants as potential factors in risk for PBC.
INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic and progressive biliary disease, characterized by a destructive granulomatous cholangitis and loss of tolerance to ubiquitous mitochondrial antigens. 1 Epidemiological data indicate important interactions between environmental and genetic factors in PBC predisposition and cumulative biological data identify an interplay of adaptive and innate immunity as integral to disease pathogenesis. 2 However, despite the well-recognized roles for immune cell populations in PBC pathophysiology, understanding of the molecular pathways underpinning PBC remains limited and needs to be improved. 3 Results of genome-wide association surveys (GWAS) confirmed association of PBC not only with the previously known human leukocyte antigen class II locus, but also many other novel nonhuman leukocyte antigen loci encompassing genes involved in immunity. 4 Thus, for example, the first GWAS data set and followup studies available for PBC identified not only the IL12A gene, but also genes encoding other components of the interleukin-12 (IL-12) signaling pathway (IL12RB2 and STAT4) as well as the interferon response factor 5 gene as PBC risk loci. These findings have since been replicated and extended. 5 --8 Importantly, these data also identify many of the immune-related loci conferring risk for PBC to be shared with rheumatoid arthritis, celiac disease, systemic lupus erythematosus and other autoimmune diseases that appear with increased frequency in PBC patients and their families. Although some of the non-human leukocyte antigen PBC risk loci containing immunologically relevant genes have been subjected to further analyses, several of the more recently identified susceptibility regions remain relatively uncharacterized. Two such immunologically relevant loci that we have prioritized, include the CLEC16A (Ctype lectin domain family 16 member A)--SOCS1 (suppressor of cytokine signaling 1) locus at chromosome 16p13 and the Spi-B protein (SPIB) locus at chromosome 19q13. At the CLEC16A-SOCS1 locus, for example, CLEC16A (aka KIAA0350) encodes a tyrosinebased activation motif-containing protein with likely effects on immune cell signaling, 9 while the SOCS1 gene product has integral roles in modulating cytokine and toll-like receptor-driven signaling pathways that regulate immune responsiveness. 10, 11 The CLEC16A-SOCS1 locus has already been implicated in risk for celiac disease, 12 multiple sclerosis, 13 Type 1 diabetes 9 and immunoglobulin A deficiency 14 and its association with PBC as well was initially flagged at a low level of significance by a Canadian PBC GWAS analysis and then formally statistically demonstrated in a UK-based PBC GWAS. However, in the former of these two studies, the singlenucleotide polymorphism (SNP) giving the strongest association signal was located just upstream of the SOCS1 gene, while in the latter, the most significant SNP at this locus was located in the CLEC16A gene, which maps over 70 kb upstream of SOCS1. This locus is genetically complex, and in multiple sclerosis a recent study based on linkage disequilibrium patterns in the region and logistic regression analysis, suggested that this region harbors independent disease risk loci.
15 SPIB is also a plausible candidate gene for PBC based on both GWAS data and data implicating the SPIB protein in both B-cell antigen receptor signaling and development of T cells and of plasmacytoid dendritic cells involved in inflammatory responses. 7, 8 This locus has not, however, emerged as a risk locus for autoimmune diseases other than PBC.
Knowledge of specific risk relevant genes underpinning PBC remains limited and one factor thought to be important are contributions to risk from rare gene variants not amenable to discovery via conventional GWAS, but requiring costly sequencing efforts. This possibility is strongly supported by the recent discovery of rare variants in the sialic acid acetylesterase (SIAE) gene that occur significantly more frequently in patients with rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis than in healthy controls. 16 The SIAE enzyme, which removes 9-O-acetyl moieties from sialic acid, has been independently implicated in autoimmunity by the immunological phenotype of SIAE-deficient mice and by its potential to regulate B-cell immune responses via 9-O-acetylation of a-2,6-linked glycans that modulate activity of the CD22 B-cell inhibitory receptor. 17 This finding has not been extensively pursued, although a Met89Val variant was not associated with type 1 diabetes mellitus and Graves' disease in one study of a Polish population. 18 Through high-density genotyping across the CLEC16A-SOCS1 and SPIB loci and direct sequencing across the SIAE locus, we identify multiple disease variants across the CLEC16A-SOCS1 and SPIB loci and show that variants within each of the CLEC16A and SOCS1 gene contribute independently to the risk for PBC. We additionally demonstrate the presence of functional variants in the SIAE gene in patients with PBC.
RESULTS
Evidence for independent association of CLEC16A and SOCS1 variants with risk for PBC In our initial PBC GWAS analysis, we found suggestive, but not significant, evidence for PBC association with the CLEC16A-SOCS1 locus, with a SNP (rs243324) located about 5.5 kb upstream of the SOCS1 coding sequence giving the strongest association in the region. This locus failed to achieve genome-wide significance in our analysis, but was also identified in a subsequent UK-based PBC GWAS. In this latter study, the most significant SNP mapped to intron 19 of CLEC16A, about 166 kb upstream of the SOCS1 gene. To better ascertain the source of the association signal at this locus, we genotyped our full study cohort (1450 cases and 2967 controls) for 57 SNPs spanning a 450-kb genomic region encompassing the CLEC16A and SOCS1 genes as well as several very small genes, transitional protein 2 and protamine 1-3, that map about 12 kb downstream of SOCS1 (Table 1) . From this analysis, 26 SNPs achieved the significance thresholds set for this study (Po10 Table 1 ). In all, 15 other SNPS flanking the SOCS1 gene region, 7 SNPs in or near the TPN2 and protamine genes and 10 SNPs within various CLEC16A gene introns also achieved nominal significance and analysis of the linkage disequilibrium patterns among the markers revealed these SNPs to constitute three major haplotype blocks, two across the CLEC16A gene and the third, a 27-kb region, encompassing the SOCS1, transitional protein 2 and protamine genes (Supplementary Figure 1) . Importantly, this analysis revealed the most strongly associated SNP in the single-point analysis (rs243325) to be in strong linkage disequilibrium with five other disease-associated SNPs mapping 3 0 to SOCS1 (pairwise r 2 ranging between 0.66 and 0.93 and D 0 between 0.88 and 0.99). Within the two haplotype blocks across the CLEC16A gene, the strongest association signal (P ¼ 4.85 Â 10 À7 , OR¼ 1.46) came from the rs58102322 SNP located in intron 18. The rs12924729 SNP initially reported in the UK PBC GWAS 8 was also among the significant SNPs at this locus (P ¼ 6.73 Â 10 À6 , OR ¼ 1.25), but shows negligible LD with rs58102322 and maps within a distinct haplotype block within the gene.
To investigate the extent to which SNPs within the SOCS1 vs the CLEC16A haplotype block contribute to the disease association at this locus, conditional logistic regression analysis was undertaken, with each of the test SNPs conditioned on the effect of the other SNPs. Three SNPs, rs58102322 and rs12924129 (intronic variants in the CLEC16A) and rs243325 (SOCS1 5 0 intergenic region) remained significant after conditioning sequentially on the most significant markers (Supplementary Table 2 ) strongly suggesting that there are multiple independent variants influencing PBC risk in this region. This conclusion is consistent with results of haplotype analyses incorporating these three risk loci (Table 2A) , which reveal effects on risk for this locus (omnibus test: P ¼ 2.61 Â 10 À14 ) and for a risk allele haplotype (AAG, P ¼ 5.36 Â 10
À8
; OR ¼ 1.67) and a protective allele haplotype (GGA, P ¼ 3.93 Â 10 À10 ; OR ¼ 0.52) at the locus to be much stronger than for any single SNP or any other allele combination at these three loci. Thus at this locus, risk associated with PBC appears to be largely determined by complementary haplotypes, which might reflect effects from as-of-yet unidentified single variant(s) or from epistatic interactions among the three loci.
To further explore the relative influence of these variants on disease susceptibility, the combined contribution of the three risk alleles at the rs12924729 (G), rs58102322 (A) and rs243325 (A) loci was also explored using logistic regression analysis (Table 2B) . For this analysis, the effect of carrying risk genotypes at the CLEC16A gene rs12924729 and rs58102322 loci was evaluated in the context of presence or absence of the risk genotypes at the SOCS1 rs243325 locus. The results revealed the OR to be significantly increased by combining carriage of rs12924729 and rs58102322 risk alleles with (OR ¼ 3.66; 95% CI ¼ 1.58 --8.46; P ¼ 0.002) compared with without (OR ¼ 2.60; 95% CI ¼ 1.00 --6.77; P ¼ 0.05) rs243325 risk alleles. When compared with all the other allele combinations, the combination of all three risk alleles has an effect size, 1.57 (95% CI ¼ 1.28 --1.94), higher than that of any individual SNP at this locus. Thus, addition of the rs243325 risk allele to the other two risk alleles substantially increases risk for disease as is in keeping with independent effects of these alleles on risk.
Fine mapping of the PBC-associated SPIB locus To refine and further validate the SPIB locus, we genotyped all cases and controls for 27 SNPs across an B60-kb region encompassing the SPIB gene and two other genes, polymerase delta 1 and myosin-binding protein 2 that map 1 kb upstream and 3.9 kb downstream, respectively, of SPIB. This analysis identified 11 SNPs at this locus to be significantly associated with PBC, 3 of which achieved P-values o5 Â 10 À8 (Table 3, Supplementary  Table 3 ; Figure 2 ) and almost all of which map within one of two haplotype blocks across the region (Supplementary Figure 2) . The most significant SNP at this locus was an intronic polymorphism, rs34944112 (P ¼ 3.65 Â 10 À9 ; OR¼ 1.49, 95% CI ¼ 1.31 --1.70), which was in strong LD (r 2 ¼ 0.96; D 0 ¼ 0.98) with another significantly associated SNP, the rs3745516 SNP identified as a PBC risk locus in the previous GWAS studies (P ¼ 1.93 Â 10 À7 ; OR ¼ 1.30). To further explore the contributions of these SNPs to the association signal, conditional logistic regression analysis was then performed again incorporating all test SNPs in the analysis. After conditioning on each marker, only the most significantly associated SNP in the region, rs34944112 remained strongly significant (Supplementary Table 4 ), the power for detecting an ORX1.3 being 490%. These findings suggest that this variant functions independently to confer much of the effect on risk at this locus.
Functionally deleterious SIAE gene mutations and PBC To assess whether SIAE gene variants are relevant to risk for PBC, we resequenced all 10 exons of this gene in 381 unrelated individuals randomly chosen from our cohort of PBC cases. Results of this analysis revealed a total of 12 point substitutions among the patients, 6 of which were non-synonymous changes that were found in 10 of 381 cases but that occurred only once in 648 controls (Table 4) ; P ¼ 0.0003. Among the non-synonymous polymorphisms, two encode SIAE protein species, F404S and T312M, previously shown to be catalytically defective and one encodes a species, M89V, reported to be catalytically intact (but not secreted). By contrast, three other polymorphisms detected in the patients encode variants, F199C, P356L and Q382R, that have not been previously described and have unknown functional effects.
To allow assessment of the frequency at which biologically relevant SIAE variants occur in PBC patients, we next explored the functional properties of the F199C, P365L and Q382R species. To this end, cDNAs encoding each of these proteins as well as the wild-type SIAE protein or a known catalytically dead SIAE mutant (S127A) were expressed in 293T cells and esterase activity of anti-SIAE immunoprecipitates from these cells then assayed. To screen for a secretory defect, SIAE levels were also assessed in culture supernatants and compared between the supernatants and lysates. Results of these analyses revealed catalytic activity to be severely reduced for the F199C variant, but essentially normal for the Q382R and P356L variant proteins (Figure 3 ). The F199C Figure 1 . Association plots for the CLEC16A-SOCS1 locus. Strength of the associations and recombination rates estimated from HapMap data for genotyped SNPs are shown for the SOCS1 loci. Both current fine-mapping data (diamonds) and genome-wide association data from a prior study of a subset of this cohort (circles) are shown. The extent of linkage disequilibrium with the most significant polymorphisms is indicated by the size of each data point; larger data points indicate stronger linkage disequilibrium. Chromosomal positions for each gene region are indicated by the arrows, with the arrow direction representing the orientation of translation. Linkage disequilibrium was calculated using observed data in PLINK.
protein was also poorly secreted into culture supernatants. Thus, one of the three variants, F199C appears to be functionally defective. On the basis of these findings and the sequence data revealing presence of the F199C variant in 3 of our PBC cases, and variants encoding other functionally impaired SIAE species in 3 more subjects, it appears that 6 of the 381 cases tested here have a functionally defective SIAE variant, and 2 further patients are homozygote for a secretory defective variant. By contrast, in 648 healthy Caucasian controls of European descent, functionally relevant SIAE variants were identified in only two individuals and in 1351 samples of European American origin for which SIAE exome sequencing data are available (http://snp.gs.washington.edu/EVS/), (B) Association study of all possible gene combinations of the three independent PBC-associated variants at the CLEC16A-SOCS1 locus. For calculation of OR, the reference was the allele combination with the lowest effect on risk. ; Fisher's exact test).
DISCUSSION
Our current study in which we focus on further refining nonhuman leukocyte antigen association with PBC, builds on recent data pinpointing the CLEC16A-SOCS1 and SPIB loci as risk loci for PBC and that identifying SIAE gene variants as risk alleles for several autoimmune diseases. Our findings confirm the presence of disease-associated SNPs across the CLEC16A-SOCS1 and SPIB gene loci and identify a number of new potential PBC markers at each of these loci. We also demonstrate that 10 of the 381 PBC cases studied here carry non-synonymous point substitutions in the SIAE gene, 2 of which were previously shown to encode functionally defective proteins (F199C and T312M) and 1 of which was identified for the first time in this study and shown here to encode catalytically impaired protein (F199C). Other variants were also detected in the patients, including one other, which was the only variant found in the homozygous state and, which has been shown previously to encode a secretory defective, but functional protein (M89V). These results thus provide the first evidence for a potential role of SIAE variants in PBC. The current data confirm PBC association with the CLEC16A-SOCS1 locus and the statistical data gleaned from conditional, haplotype and combination analyses provide compelling evidence for independent contributions of CLEC16A and SOCS1 alleles to risk of developing PBC. This conclusion is consistent with the wellrecognized role for SOCS1 and likely role for CLEC16A in immune regulation. SOCS1 is a well-established immune cell signaling inhibitor that functions downstream of cytokine receptors to inhibit JAK-STAT-mediated induction of interferon-g, IL-2, IL-6, IL-4 and tumor necrosis factor-a and many other proinflammatory cytokines. 19 Mice lacking SOCS1 protein thus exhibit cellular hyperreactivity to many such cytokines and rapidly develop a multi-organ inflammatory disease associated with profound activation of hepatic lymphocytes and death by age 3 weeks due to fulminating hepatitis. 20, 21 Specific loss of SOCS1 in hepatocytes also renders mice more susceptible to ConA-induced hepatitis, 22 while SOCS1-specific deletion in T cells promotes Th1, but impairs Th17 cell development. 23 Thus, SOCS1 regulates T-cell differentiation pathways that are integral to maintenance of immune cell homeostasis. Roles for both SOCS1 and CLEC16A variants in PBC are thus in keeping with genetic association data implicating this locus in other autoimmune diseases and with the cumulative biological understanding of the two proteins.
The SPIB locus was initially revealed as a likely PBC risk locus by our GWAS data showing an association signal that just missed genome-wide significance (P ¼ 9.12 Â 10
À7
; OR¼ 1.27) at the rs3745516 SNP locus within a SPIB gene intron. 6 Strong evidence for this gene's association with PBC was then provided by a followup meta-analysis of Italian and Canadian GWAS data 7 and a subsequent UK PBC GWAS. 8 Our current findings provide added evidence for SPIB involvement in PBC, revealing strong association of several intronic SNPs with risk and suggesting this locus's effect on risk to be primarily attributable to the most significant variant at this locus, rs34944112. Interestingly, another significant association signal from the region came from the rs11546996 SNP, which encodes an alanine to proline substitution in exon 4 of the SPIB gene. This conservative substitution, however, would be expected to have little functional relevance, a prediction consistent with the conditional analysis results showing no independent effect of this SNP on risk. Defining the disease-causal SNP at this locus will require further biological studies, but an effect of the SPIB-encoded Spi-B transcription factor on risk is in keeping with its prerequisite role in regulating both lineage commitment during haematopoiesis and differentiation of mature lymphocyte and dendritic cell populations. 24, 25 The SPIB gene is also of particular potential interest as this locus has not, as of yet, been implicated in other autoimmune diseases and may prove to represent a PBC-specific risk locus. This possibility and the definition of the disease relevant allele at this locus, however, require further investigation through expanded genetic and functional studies.
In contrast to most of the gene loci now implicated in PBC susceptibility, SIAE emerged as a candidate gene for PBC in the context of a resequencing screen for SIAE variants in other autoimmune diseases. Involvement of this gene in such diseases was initially suggested by the enhanced B-cell activation and auto-antibody production observed in SIAE-deficient mice and Figure 2 . Association plots for the SPIB locus. Strength of the associations and recombination rates estimated from HapMap data for genotyped SNPs are shown for the SPIB locus. Both fine-mapping data from this study (diamonds) and genome-wide association data from a prior study of a subset of this cohort (circles) are shown. The extent of linkage disequilibrium with the most significant polymorphisms is indicated by the size of each data point; larger data points indicate stronger linkage disequilibrium. Gene positions for each gene region are indicated by the arrows, with the arrow direction representing the orientation of translation. Linkage disequilibrium was calculated using observed data in PLINK. was then confirmed by the demonstration of functionally deleterious SIAE gene mutations in patients with rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. 16, 17 One very limited replication study in type 1 diabetes and Graves disease was negative, 18 although our systematic SIAE resequencing and functional data obtained in this study do reveal a small number of the PBC patients tested to have loss-of-function SIAE missense mutations. As genotype data were not available for our full case population, genome-wide findings were not adjusted for population stratification. However, an association of SIAE variants with PBC, as suggested by our data, is consistent with the not infrequent occurrence in PBC patients and their families of other autoimmune diseases (rheumatoid arthritis and systemic lupus erythematosus) known to be associated with SIAE variants. In our study, for example, 8 of the 10 PBC cases with a functional SIAE variant and/or a family member had one or more other autoimmune diseases. The concordance between PBC and other autoimmune diseases implies that observed PBC-gene associations may also reflect the presence of these other diseases. Sequencing studies of a much larger case/control cohort are needed to address this possibility and better delineate the frequency, repertoire and cellular consequences of rare variants in PBC and the interactions of such variants with more common variants in predisposing to PBC vs other autoimmune disease.
The SIAE locus has not been specifically implicated in PBC by prior reports. For this reason and also because there are little data on the contribution of rare variants to risk for autoimmune disease, we believe the demonstrated association of PBC with SIAE variants adds an important new dimension to the genetic understanding of such conditions. Similarly, while implicated in risk for PBC as well as other autoimmune diseases, the CLEC16A-SOCS1 locus association with PBC had not been replicated before this study and there are no published data that refine this GWASdefined risk locus. The data reported here thus provide new insights into the genetic basis of PBC and a framework for further studies using larger cohorts to address potential correlations of the gene variants reported here to PBC subphenotypes such as anti-mitochondrial antibodies status and severity.
Collectively, our current findings are in keeping with key roles for multiple immune-related genes in PBC and provide more evidence of overlap between some, but not all PBC risk alleles and those reported for other autoimmune diseases. Our data also begin the process of identifying contributory effects of rare missense mutations to risk for PBC and thus highlight the need to search for additional risk alleles by more extensive resequencing endeavors in extremely large case --control cohorts.
MATERIALS AND METHODS Subjects
The subject cohort studied here included 1450 PBC cases and 2967 controls. Another 648 'historic' controls served as a source for data on SIAE variant frequency in healthy controls. 16 Clinical characteristics of the patients have been previously reported, 5, 6 but all were diagnosed with PBC according to the American Association for the Study of Liver Disease guidelines. 1 All study subjects as well as historic controls were of Caucasian European descent and were ascertained from either the Canada, USA or Europe. The Local Institutional Review Committee provided approval for conduct of this study, and all individuals gave their informed consent.
CLEC16A-SOCS1 and SPIB SNP selection and genotyping SNPs initially tested across the 16p13 and 19q13 risk loci were selected based on at least one of the following criteria: (1) Hap Map Phase III data identifying the SNP as a Tag SNP with minor allele frequency 40.01. and r 2 threshold of 0.8) and/or (2) localization within 150 kb upstream or downstream of the SNPs at each locus most significantly associated with PBC in our GWAS and GWAS meta-analysis. Genotyping was performed Figure 3 . Functional analysis of newly identified SIAE variants. SIAE cDNAs encoding Flag-tagged versions of wild-type SIAE, a catalytically inert SIAE mutation (S127A) and three SIAE variants of unknown functional significance (F199C, P356L and Q382R) were expressed in 293 cells, the cell lysates and culture supernatants harvested 48 h later and immunoprecipitated with anti-Flag antibody ('control' refers to untransfected cells). Immunoprecipitates were split into two equivalent aliquots with one used in immunoblotting to quantitate SIAE levels and the second used to assay for esterase activity on a fluorogenic substrate. Anti-Flag antibody immunoblotting analysis of cell lysates and supernatants from 293 transfected cells is shown in the upper panel. Bottom left panel shows esterase activity of each SIAE species normalized for lysate SIAE protein levels and bottom right panel shows ratios of SIAE levels in culture supernatant relative to lysate. Each variant was tested three times and the data are shown as mean±s.e.m. 16 using the Sequenom MassArray iPLEX platform (San Diego, CA, USA) with allele-extension products plated onto a SpectroCHIP and subjected to mass spectrometry and the genotypes then called using SpectroCALLER software (Sequenom). SNP annotation was based on NCBI dbSNP Build 129.
SIAE gene sequencing
DNA was prepared by the standard phenol/chloroform extraction from genomic DNA of each subject. All 10 exons of the SIAE gene were then amplified by PCR using previously reported intronic primer pairs covering the 5 0 and 3 0 splice sites of each exon 16 and the amplicons then subjected to bidirectional automated sequencing using an Applied Biosystems 3730 DNA analyzer (Carlsbad, CA, USA). Sequence alignment and polymorphism identification were carried out using Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, MI, USA). Only the 10 exons of the SIAE gene were sequenced, that is, the sequencing primers did not cover the promoter or other regulatory regions for the gene. Data on SIAE sequences in 1351 Caucasian controls included in the multiple Exome Sequencing Project were obtained from the Exome Variant Server, NHLBI Exome Sequencing Project, Seattle, WA, USA (URL: http://evs.gs.washington.edu/EVS/) (accessed November 2011).
SIAE activity assay
To assay functionality of SIAE variants, site-directed mutagenesis with Pfu Turbo-based DNA polymerase (Stratagene, Santa Clara, CA, USA) was used to introduce selected single-nucleotide changes into full-length, C-terminal Flag-tagged human SIAE cDNA subcloned in the pcDNA3.1. vector. These cDNAs as well as cDNAs encoding wild-type and the catalytically inert SIAE were transiently transfected into HEK 293T cells, the cells then lysed in 1% NP40 in phosphate-buffered saline and the lysates as well as culture supernatants subdivided into two equal aliquots from which the esterase was immunoprecipitated using monoclonal anti-Flag antibody (Sigma, St Louis, MO, USA) and protein A Sepharose. Catalytic activities were assessed in one aliquot of the immunoprecipitated SIAE using a fluorogenic substrate, 4-methylumbelliferyl acetate (UBS), a FluoroskanII instrument (Finstrument) and Spectroscope software as described previously, 16 and the enzymatic activity levels then normalized to protein levels. Relative quantity of the Flag-tagged protein was assessed in the second aliquot as reported previously 16 using a quantitative immunoblot assay, an IR Dye 800CW-labeled goat anti-mouse immunoglobulin G secondary antibody and the LI-COR Odyssey imaging system (Lincoln, NE, USA). The assay was performed three times for each cDNA.
Statistical analyses
Individual samples with genotype call rates of o95% and SNPs with call rates of o95%, minor allele frequencies of o1%, or deviation from the Hardy --Weinberg equilibrium at Po0.001. (as assessed in controls), were removed from the analysis. In total 1450 cases, 2957 controls and 84 SNPs were included in the statistical analyses. PLINK software (v1.07) was used to assess allelic associations, R-script (http://www.rproject.org/) to generate figures and haploview software, and Haploview software, version 4.1 (http://www.broad.mit.edu/mpg/haploview), to evaluate linkage disequilibrium between pairs of SNPs. Haplotype block structure was defined according to the criteria established by Gabriel and the pairwise estimates of standardized Lewontin's disequilibrium coefficient (D 0 ), whereas the linkage disequilibrium among pairs of SNPs was characterized according to the square of the correlation coefficient (r 2 ). Conditional logistic regression analyses of multiple markers were performed using SAS v9.13 (SAS Institute Inc., Cary, NC, USA) with subsequent power analyses conducted using CATs software (http://www.sph.umich.edu/csg/abecasis/CaTS/ index.html) and an additive model. w 2 or Fisher's exact testing was performed to demonstrate association for sequence data. For allelic association tests, the threshold for declaring significance in the fine mapping studies was Po0.05/84 (o6 Â 10
À4
).
